2023-18043. Bulk Manufacturer of Controlled Substances Application: Cambrex Charles City  

  • Start Preamble

    AGENCY:

    Drug Enforcement Administration, Justice.

    ACTION:

    Notice of application.

    SUMMARY:

    Cambrex Charles City has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.

    DATES:

    Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 23, 2023. Such persons may also file a written request for a hearing on the application on or before October 23, 2023.

    ADDRESSES:

    The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

    End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    In accordance with 21 CFR 1301.33(a), this is notice that on July 3, 2023, Cambrex Charles City, 1205 11th Street, Charles City, Iowa 50616–3466, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): Start Printed Page 57132

    Controlled substanceDrug codeSchedule
    Gamma Hydroxybutyric Acid2010I
    Tetrahydrocannabinols7370I
    Amphetamine1100II
    Lisdexamfetamine1205II
    Methylphenidate1724II
    ANPP (4-Anilino-N-phenethyl-4-piperidine)8333II
    Phenylacetone8501II
    Codeine9050II
    Oxycodone9143II
    Hydromorphone9150II
    Hydrocodone9193II
    Methadone9250II
    Morphine9300II
    Oripavine9330II
    Thebaine9333II
    Opium extracts9610II
    Opium fluid extract9620II
    Opium tincture9630II
    Opium, powdered9639II
    Oxymorphone9652II
    Noroxymorphone9668II
    Fentanyl9801II

    The company plans to manufacture the listed controlled substances in bulk for conversion to other controlled substances and sales to its customers for dosage form development, clinical trials and use in stability qualification studies.

    In reference to drug codes 7360 (Marihuana), and 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

    Start Signature

    Claude Redd,

    Acting Deputy Assistant Administrator.

    End Signature End Supplemental Information

    [FR Doc. 2023–18043 Filed 8–21–23; 8:45 am]

    BILLING CODE P

Document Information

Published:
08/22/2023
Department:
Drug Enforcement Administration
Entry Type:
Notice
Action:
Notice of application.
Document Number:
2023-18043
Dates:
Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 23, 2023. Such persons may also file a written request for a hearing on the application on or before October 23, 2023.
Pages:
57131-57132 (2 pages)
Docket Numbers:
Docket No. DEA-1247
PDF File:
2023-18043.pdf